An interventional study of Acute Taurine Supplementation and Acute Placebo Supplementation in Local Muscular Endurance and Fatigue, NIRS Skeletal Muscle Mitochondrial Capacity and Acute Taurine Supplementation, sponsored by Louisiana State University and A&M College. Recruiting at 1 site in United States. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by Louisiana State University and A&M College · Not applicable, Interventional, and Basic science
The goal of this clinical trial is to determine the association between near-infrared spectroscopy (NIRS)-derived mitochondrial oxidative phosphorylation (OXPHOS) capacity of the vastus lateralis muscles, and both local muscular endurance capacity and local muscular fatigability of the thigh muscles in young adults. Additionally, this trial aims to determine the effect of acute taurine supplementation on local muscular endurance capacity and local muscular fatigability when compared to a placebo condition. The main questions it aims to answer are:
Participants will:
Participants will be recruited from the Louisiana State University campus and the Greater Baton Rouge area. Interested and potentially eligible participants will be identified based on the responses provided to questions on a prescreen assessment survey completed electronically via RedCap. These individuals will then be scheduled for the in-person Screening and Familiarization Visit which will include: a review of the informed consent form; a review of the inclusion/exclusion criteria; a self-report medical history and medication inventory; the collection of demographic information; an assessment of height and weight; an assessment of body composition via bioelectrical impedance analysis; an assessment of resting blood pressure and heart rate; the completion of the Physical Activity Readiness Questionnaire for Everyone (PARQ+) and the Global Physical Activity Questionnaire (GPAQ); an ultrasound assessment to determine adipose tissue thickness at the NIRS assessment sites; and familiarization with primary study assessments. If eligible according to the Screening and Familiarization Visit, participants will complete the NIRS Assessment Visit. Following an overnight fast (≥ 12 hours), with ≥ 24 hours since most recent exercise participation, a NIRS occlusion-based recovery kinetics approach will be used to non-invasively assess the mitochondrial OXPHOS capacity of the vastus lateralis muscle of each leg. On the day prior to this visit, participants will be asked to complete a 24-hour food log. Participants will then be asked to repeat this reported 24-hour food consumption on the day prior to each of the two remaining study assessment visits. Acute Supplementation Assessment Visit 1 will be completed following an overnight fast (≥ 12 hours), with ≥ 72 hours since most recent exercise participation and ≥ 48 hours following the NIRS Assessment Visit. During Acute Supplementation Assessment Visit 1, a baseline blood sample (10 ml) will be collected upon participants' arrival. Participants will then ingest either a taurine or placebo supplement depending on a randomized supplementation order. Next, participants will wait for 60 minutes following supplement ingestion before having another blood sample (10 ml) collected. Then participants will complete the submaximal, single-leg extension (SLE) isotonic contraction time-to-exhaustion (TTE) test on a randomly determined leg, followed by the 4-minute repeated, single-leg maximal voluntary isometric contraction (MVIC) fatigue index test on the contralateral leg. 7-10 days after Acute Supplementation Assessment Visit 1, following a ≥ 12 hour overnight fast and ≥ 72 hours since most recent exercise participation, participants will complete Acute Supplementation Assessment Visit 2. During this visit, all visit procedures will be conducted identically relative to Acute Supplementation Assessment Visit 1, but participants will consume the alternate supplement according to a randomized supplementation order. The 7-10 days between acute supplementation assessment visits will serve as a standard washout period. An unblinded member of the study team will be responsible for randomizing the supplementation order and preparing the supplements for all participant visits. This unblinded study team member will not be involved in any other aspects of data collection, data processing, or data analysis. All study visits will be conducted in the LSU Exercise Physiology Laboratory.
METHODS
Four-Minute Repeated, Single-Leg Maximal Voluntary Isometric Contraction Fatigue Index Test. A multimodal dynamometer (Humac NORM) will be used to perform this assessment on the quadriceps muscles/knee extensors. Participants will be set up on the device with the knee fixed at a 60° angle relative to full knee extension ROM. Participants will perform 5-second MVICs interspersed by 5-second rest intervals for four consecutive minutes (for a total of 24 repeated MVICs). The measured MVIC torques will be used to calculate fatigue index as the main outcome variable from this test. To calculate fatigue index, the investigators will first take the highest torque achieved from the first three MVICs (i.e., kicks 1-3) and the highest torque achieved from the final three MVICs (i.e., kicks 22-24), then use the following equation:
((Peak torque from first 3 MVICs - Peak torque from final 3 MVICs)/(Peak torque from first 3 MVICs)) x 100. A Train.Red NIRS probe and surface EMG probes will be placed on the vastus lateralis to assess muscle oxygen saturation and excitation during the test.
2,229 studies on the registry are indexed under Fatigue; 426 are open to participants now.
This study's planned enrollment of 34 is below the median of 54 across 1,757 interventional studies indexed under Fatigue.
Browse Fatigue studies →Louisiana State University and A&M College is the lead sponsor of 13 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will ingest six taurine capsules (6 grams of taurine)
Dietary Supplement: Acute Taurine Supplementation
Participants will ingest six placebo capsules (1.2 grams of microcrystalline cellulose)
Dietary Supplement: Acute Placebo Supplementation
Participants will ingest six taurine capsules (6 grams of taurine) following a baseline blood collection to determine baseline plasma taurine levels. 60 minutes following ingestion, there will be an additional blood collection to determine post-supplementation plasma taurine levels. Participants will then perform exercise assessments. The order of taurine supplementation relative to placebo supplementation will be randomized in a double-blind crossover with 7-10 days separating each condition.
Participants will ingest six placebo capsules (1.2 grams of microcrystalline cellulose) following a baseline blood collection to determine baseline plasma taurine levels. 60 minutes following ingestion, there will be an additional blood collection to determine post-supplementation plasma taurine levels. Participants will then perform exercise assessments. The order of placebo supplementation relative to taurine supplementation will be randomized in a double-blind crossover with 7-10 days separating each condition.
Single Leg Extension Time-to-Exhaustion
Within-participant comparison of single-leg extension time-to-exhaustion (a measure of local quadriceps muscular endurance capacity) when comparing the acute taurine supplementation and acute placebo supplementation conditions
Time frame: From Acute Supplementation Assessment Visit 1 to Acute Supplementation Assessment Visit 2, 7-10 days
Single-Leg Muscular Fatigue Index
Within-participant comparison of fatigue index during 24 repeated maximal voluntary isometric contractions (a marker of local quadriceps muscular fatigability) when comparing the acute taurine supplementation and acute placebo supplementation conditions
Time frame: From Acute Supplementation Assessment Visit 1 to Acute Supplementation Assessment Visit 2, 7-10 days
Correlation Between Vastus Lateralis NIRS Rate Constant and Single-Leg Extension Time-to-Exhaustion
The correlation between the rate constant of the vastus lateralis derived from the NIRS occlusion-based recovery kinetics assessment (a marker of mitochondrial OXPHOS capacity) and single-leg extension time-to-exhaustion (a maker of local quadriceps muscular endurance capacity).
Time frame: From the NIRS Assessment Visit to Acute Supplementation Assessment Visit 2, approximately 2-3 weeks
Correlation Between Vastus Lateralis NIRS Rate Constant and Single-Leg Muscular Fatigue Index
The correlation between the rate constant of the vastus lateralis derived from the NIRS occlusion-based recovery kinetics assessment (a marker of mitochondrial OXPHOS capacity) and single-leg muscular fatigue index (a maker of local quadriceps muscular fatigability).
Time frame: From the NIRS Assessment Visit to Acute Supplementation Assessment Visit 2, approximately 2-3 weeks
Plan to share: Undecided — The investigators have not yet decided on the individual participant data sharing plan. The investigators will determine at a later stage whether data will be shared and the nature of the data sharing.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Louisiana State University and A&M College